From August 15 to 17, 2025, the 31st China International Medical Instruments and Equipment Exhibition & Technical Exchange (China-Hospeq 2025) was held at the China National Convention Center in Beijing. AccuMedical made a grand debut with its full portfolio of neurointervention solutions.
This year’s exhibition, themed “Meeting Health Challenges, Seizing Development Opportunities,” actively implements the new development philosophy to support the construction of a Healthy China and the Health Silk Road.
China-Hospeq 2025 covered 22,000 square meters, featuring more than 200 companies and organizations from over 10 countries and regions including China, Germany, the United States, the Netherlands, and Sweden. Exhibits spanned fields such as medical imaging, radiotherapy, clinical diagnostics, medical robotics, AI-based medical large models, ophthalmology, and mobile healthcare. Dedicated theme zones were also set up for initiatives including China-Africa Health Partnership, Medical Innovation, High-Quality Development of Public Hospitals, and Healthy Lifestyles, highlighting products, technologies, and solutions tailored to the health needs of China and Belt and Road countries.
Among the core products showcased by AccuMedical was the newly upgraded Lattice® NEXT Flow Diverter. With its groundbreaking “non-extended” headless guidewire design and optimized stent delivery system, the device significantly enhances the clinical experience in intracranial aneurysm treatment. In particular, it enables smoother navigation and more precise deployment in tortuous vessels. Powered by multiple innovative technologies, Lattice® NEXT reduces procedural complexity, shortens operation time, and improves patient outcomes, ushering in the “automatic gear” era of intracranial aneurysm treatment and fully addressing clinical needs.
To date, AccuMedical has obtained NMPA approval for 9 innovative products, including Lattice®, Lattice® NEXT, attractor®, cosine®, and sine®, covering the full spectrum of neurointervention scenarios from hemorrhagic stroke and ischemic stroke to access support. The company has filed 135 patent applications, of which 76 have been granted, building a robust intellectual property portfolio with strong barriers. Thanks to its sustained innovation and solid industrialization achievements, AccuMedical has been recognized as a National High-Tech Enterprise (2023) and a National-Level “Little Giant” Enterprise (2024).
As international exchange in the global medical field continues to deepen, Chinese neurointervention companies represented by AccuMedical are injecting continuous innovation into the research and treatment of cerebrovascular diseases worldwide. We firmly believe that the future of global healthcare will be even more dynamic, with medical innovations from China shining brightly on the world stage.